|
|||||
|
|
Results from a 9‐year Intensive Safety Surveillance Scheme (IS3) in miglustat (Zavesca®)‐treated patients |
|
| Authors: | Monika Brand Audrey Muller Jonathan Alsop Ivo N. van Schaik Bruno Bembi Derralynn Hughes |
| Affiliation: | 1. Actelion Pharmaceuticals Ltd, Allschwil, Switzerland;2. Numerus Ltd, Wokingham, UK;3. Academic Medical Center, Amsterdam, the Netherlands;4. Regional Coordinator Centre for Rare Diseases, Azienda Ospedaliera Santa Maria della Misericordia di Udine, Udine, Italy;5. Royal Free and University College Medical School, London, UK |
| Abstract: | |
| Keywords: | Gaucher disease lysosomal storage disease miglustat safety surveillance pharmacoepidemiology |